1. Academic Validation
  2. Pachymic acid inhibits growth and metastatic potential in liver cancer HepG2 and Huh7 cells

Pachymic acid inhibits growth and metastatic potential in liver cancer HepG2 and Huh7 cells

  • Biol Pharm Bull. 2022 Oct 22. doi: 10.1248/bpb.b22-00440.
Feng Jiang 1 Tieming Zhu 1 Chunfeng Yang 1 Yang Chen 1 Zhidong Fu 1 Lihui Jiang 1 Yongzhi Liu 1
Affiliations

Affiliation

  • 1 Department of General Surgery, Afficiated Xiaoshan Hospital, Hangzhou Normal University.
Abstract

Pachymic acid (PA), exacted from Polyporaceae, has been known for its biological activities including diuretic, dormitive, anti-oxidant, Anti-aging, anti-inflammatory and Anticancer properties in several types of diseases. Recently, studies have demonstrated that PA could suppress cell growth and induce cell Apoptosis in different kinds of Cancer cells. But the underlying mechanisms remain poorly elucidated. In the current study, we investigated the effect of pachymic acid on liver Cancer cells and its underlying mechanisms. Our results evidenced that pachymic acid effectively inhibited the cell growth and metastatic potential in HepG2 and Huh7 cells. Mechanistically, we revealed that pachymic acid triggered cell Apoptosis by increasing Caspase 3 and Caspase 9 cleavage, upregulating Bax and cytochrome c expression, while reducing the expression of Bcl2. Besides, pachymic acid could markedly inhibit the cell invasion and migration and cell metastatic potential by mediating EMT markers and metastasis-associated genes in HepG2 and Huh7 cells. In addition, we demonstrated that FAK-Src-JNK-MMP2 axis was involved in PA-inhibited liver cell EMT. Together, these results contributes to our deeper understanding of the anti-cancer effects of pachymic acid on liver Cancer cells. This study also provided compelling evidence that PA might be a potential therapeutic agent for liver Cancer treatment.

Keywords

Apoptosis; EMT;; Liver cancer; Pachymic acid.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-N0371
    ≥99.0%, Triterpenoid Compound
    Akt; ERK